BioCancell Therapeutics

17 articles about BioCancell Therapeutics

• BioCanCell Announces Terms of $25M Funding Round

  1/23/2018

  The investment will be priced at NIS 1.60 per share ($0.46 at current exchange rates), reflecting a Company valuation of approximately $51 million on a fully-diluted basis.

• 

  Shareholders Turn Down Tender Offer to Take BioCanCell Private

  12/28/2017

  Approximately 5.9 million shares were necessary for the tender to be accepted.

• Investors Initiate Tender Offer to Take BioCanCell Private Ahead of Planned Fundraising Round

  12/12/2017

  Shareholders have until Sunday, December 24th, 2017, at 3:00pm IST to vote their acceptance of the offer.

• BioCanCell Announces Updated Results from the Phase II Clinical Trial of BC-819 and BCG in Patients With Bladder Cancer

  11/16/2017

  Patients are being followed for up to 2 years, and the median follow-up at the time of the analysis is approximately 18 months.

• BioCanCell Announces Exploration of Funding Round Conditioned on a Going Private Transaction and Business Development Update

  10/30/2017

  The investors have informed BioCanCell that the execution of the Private Investment is dependent on BioCanCell’s becoming a private company.

• BioCancell Therapeutics Announces Appointment Of Ms. Ruti Alon To Board Of Directors

  8/14/2017

• Cobra Biologics Ltd. And BioCancell Therapeutics Announce Agreement To Manufacture Promising Cancer Therapy Drug

  3/3/2014

• BioCancell Therapeutics to Commence Enrollment of Phase IIb Pancreatic Cancer Clinical Trial

  10/6/2011

• BioCancell Therapeutics Successfully Raises $5.1 Million in Public Offering

  11/23/2010

• Tikcro Technologies Announces Results of BioCancell Therapeutics' US FDA Phase I/IIa Pancreatic Cancer Trial

  11/2/2010

• BioCancell Therapeutics Announces Success in Phase I/IIa Pancreatic Cancer Clinical Trial

  11/1/2010

• Tikcro Technologies Announced BioCancell Therapeutics Receives U.S. FDA Approval to Continue Phase IIb Superficial Bladder Cancer Clinical Trial and Interim Results

  4/30/2010

• US Department of Health and Human Services Grants Orphan Drug Status to BioCancell Therapeutics's Ovarian Cancer Drug

  8/24/2009

• USA FDA Allows BioCancell Therapeutics to Commence Phase I/IIa Ovarian and Pancreatic Clinical Trials

  1/14/2009

• VGX International Signs a Master Product Sale Agreement with BioCancell Therapeutics of Israel to Supply Plasmid for Its Multiple Clinical Programs

  10/27/2008

• Tikcro Technologies Closes Funding into BioCancell Therapeutics

  7/31/2008

• Tikcro Technologies Allocates $2.5 Million of Funding into BioCancell Therapeutics

  6/23/2008